The Danish biotech’s recruitment drive began last summer when data from an early-stage trial of the drug—petrelintide—showed ...

Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to co-develop a weight-loss treatment as the companies double down on ...

Roche's strong U.S. presence and diversified product portfolio may mitigate the impact of potential tariffs, making it a ...

The obesity drug market has experienced a seismic shift in recent years, with Novo Nordisk's (NOV: N) Wegovy (semaglutide) ...

Zealand Pharma (ZLDPF) and Roche (RHHBY) entered a collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with overweight ...

Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...

Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Danish biotech Zealand Pharma's obesity drug candidate, as the two firms seek to ...

And Big Pharmas are making bigger moves now too. Last week, Roche announced a deal with Zealand Pharma, a Danish biotech with four obesity peptides in development including a differentiated ...

Roche Holding agreed a collaboration and licensing deal with Zealand Pharma to co-develop a weight-loss treatment using its CT-388 medicine combined with Zealand Pharma’s petrelintide.

Zealand Pharma will receive up to $5.3 billion under its obesity drug partnership with Roche. Roche and Zealand Pharma will co-commercialize petrelintide in the U.S. and Europe, sharing profits 50/50.

Roche Holdings AG (OTC:RHHBY) on Wednesday announced data from MUSETTE Phase 3 trial of a high dose of Ocrevus (ocrelizumab) ...

Zealand Pharma is on a hiring spree as it bets on the success of its experimental weight-loss treatment that last month saw Swiss healthcare group Roche swoop in to partner on the drug’s ...